Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Strategic Priorities - The company aims to maximize the market potential for CARVYKTI, particularly following recent data presented at ASCO, which indicates that up to one-third of patients in the CARTITUDE-1 study, who are heavily pretreated, can achieve a 5-year treatment-free cancer remission [2] - This data is significant as it suggests a potential "functional cure" for multiple myeloma, a condition historically viewed as incurable, where patients typically cycle through various therapies before succumbing to the disease [2]